Glaukos Co. (NYSE:GKOS - Get Free Report) COO Joseph E. Gilliam sold 59,801 shares of Glaukos stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $100.47, for a total value of $6,008,206.47. Following the sale, the chief operating officer now directly owns 101,845 shares in the company, valued at $10,232,367.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Glaukos Stock Performance
Shares of NYSE GKOS opened at $99.71 on Thursday. The company has a current ratio of 5.34, a quick ratio of 4.78 and a debt-to-equity ratio of 0.77. The stock has a 50 day simple moving average of $91.38 and a 200-day simple moving average of $79.70. The company has a market cap of $4.93 billion, a PE ratio of -35.87 and a beta of 1.08. Glaukos Co. has a 12-month low of $45.38 and a 12-month high of $102.33.
Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.07). The business had revenue of $82.40 million for the quarter, compared to analyst estimates of $81.00 million. Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The business's quarterly revenue was up 15.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.53) earnings per share. On average, equities research analysts forecast that Glaukos Co. will post -2.18 EPS for the current year.
Analyst Ratings Changes
Have You Seen Elon’s New A.I. Device? (Picture Inside)
From InvestorPlace | Ad
A strange new era for mankind is upon us...
And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day.
Elon believes A.I. is advancing so fast...
This strange new device to protect us against that A.I. threat...
A number of brokerages have recently issued reports on GKOS. Wells Fargo & Company lifted their target price on Glaukos from $83.00 to $103.00 and gave the stock an "overweight" rating in a research report on Thursday, February 22nd. Truist Financial reaffirmed a "buy" rating and set a $110.00 target price on shares of Glaukos in a research report on Monday. Citigroup boosted their price objective on Glaukos from $107.00 to $120.00 and gave the company a "buy" rating in a report on Monday, March 25th. Piper Sandler boosted their price objective on Glaukos from $90.00 to $105.00 and gave the company an "overweight" rating in a report on Friday, December 22nd. Finally, Stifel Nicolaus reissued a "buy" rating and issued a $110.00 price objective on shares of Glaukos in a report on Wednesday, April 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Glaukos currently has a consensus rating of "Moderate Buy" and a consensus price target of $98.30.
Check Out Our Latest Research Report on GKOS
Hedge Funds Weigh In On Glaukos
Several hedge funds and other institutional investors have recently made changes to their positions in GKOS. Point72 Asset Management L.P. boosted its position in shares of Glaukos by 154.8% during the fourth quarter. Point72 Asset Management L.P. now owns 1,152,600 shares of the medical instruments supplier's stock worth $50,346,000 after buying an additional 700,200 shares during the period. Balyasny Asset Management L.P. lifted its position in Glaukos by 304.3% in the first quarter. Balyasny Asset Management L.P. now owns 691,899 shares of the medical instruments supplier's stock worth $34,664,000 after purchasing an additional 520,758 shares during the period. Invesco Ltd. lifted its position in Glaukos by 45.5% in the third quarter. Invesco Ltd. now owns 1,450,033 shares of the medical instruments supplier's stock worth $109,115,000 after purchasing an additional 453,756 shares during the period. Norges Bank acquired a new stake in Glaukos in the fourth quarter worth approximately $17,593,000. Finally, Morgan Stanley lifted its position in Glaukos by 58.0% in the fourth quarter. Morgan Stanley now owns 809,206 shares of the medical instruments supplier's stock worth $35,346,000 after purchasing an additional 297,021 shares during the period. 99.04% of the stock is currently owned by institutional investors and hedge funds.
About Glaukos
(
Get Free Report)
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
